KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Asset Utilization Ratio (2019 - 2025)

Esperion Therapeutics' Asset Utilization Ratio history spans 7 years, with the latest figure at 0.97 for Q4 2025.

  • For Q4 2025, Asset Utilization Ratio fell 3.83% year-over-year to 0.97; the TTM value through Dec 2025 reached 0.97, down 3.83%, while the annual FY2025 figure was 1.0, 17.66% down from the prior year.
  • Asset Utilization Ratio reached 0.97 in Q4 2025 per ESPR's latest filing, up from 0.85 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 1.01 in Q4 2024 to a low of 0.21 in Q2 2022.
  • Average Asset Utilization Ratio over 5 years is 0.55, with a median of 0.5 recorded in 2023.
  • The largest YoY upside for Asset Utilization Ratio was 2945.93% in 2021 against a maximum downside of 73.77% in 2021.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.26 in 2021, then rose by 4.12% to 0.27 in 2022, then soared by 102.37% to 0.54 in 2023, then surged by 85.43% to 1.01 in 2024, then decreased by 3.83% to 0.97 in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Asset Utilization Ratio are 0.97 (Q4 2025), 0.85 (Q3 2025), and 0.8 (Q2 2025).